Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230599 | 0.70 | DHFR (0.39) | — | |
| SCHEMBL11148032 | 0.61 | CSNK1D (0.34) | CSNK1DCSNK1EKCNH2ACVR1 | |
| SCHEMBL29334357 | 0.60 | PRKACA (0.39) | CSNK1DCSNK1EKCNH2MALT1ACVR1 | |
| SCHEMBL11142305 | 0.59 | CSNK1D (0.36) | CSNK1DCSNK1EKCNH2 | |
| SCHEMBL13694793 | 0.59 | LMNA (0.48) | — | |
| SCHEMBL28976231 | 0.58 | CSNK1D (0.43) | CSNK1DCSNK1EKCNH2 | |
| SCHEMBL38656209 | 0.57 | CSNK1D (0.38) | CSNK1DCSNK1EKCNH2MALT1ACVR1 | |
| SCHEMBL2944138 | 0.57 | CHRNA7 (0.47) | MALT1 | |
| SCHEMBL22589151 | 0.57 | CHRNA7 (0.47) | MALT1 | |
| SCHEMBL14839527 | 0.57 | BCDIN3D (0.35) | CSNK1DCSNK1EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | CSNK1D 283/4885CSNK1E 329/4885KCNH2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.